Infection with Salmonella spp. is the second most reported zoonotic disease in humans with 60 050 reported cases in 2021 in the European Union (EU) and Salmonella is associated with the highest number of foodborne outbreaks. The overall EU trend of salmonellosis incidence for the years 2017 to 2021 have not changed significantly. To prevent foodborne diseases such as salmonellosis, human surveillance systems at different levels are essential to monitor the disease and to have an early detection and response to outbreaks.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.
This document provides practical guidance to EU/EEA Member States willing to implement a pilot study for the harmonised and coordinated targeted genomic surveillance of SARS-CoV-2 at selected international points of entry (PoE), to complement national and international genomic surveillance.
In a Threat Assessment Brief released today, the European Centre for Disease Prevention and Control (ECDC) assesses the overall level of risk to the EU/EEA associated with the spread of the Omicron XBB.1.5 SARS-CoV-2 sub-lineage as low for the general population.
XBB.1.5 is a sub-lineage of the SARS-CoV-2 lineage XBB, and is currently estimated to have a large growth advantage over previously circulating lineages in North America (109%) and Europe (113%).
This report describes the external quality assessment (EQA) scheme for the European Legionnaires’ disease Surveillance network, for the detection, isolation, identification, and enumeration of Legionella spp.